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ABSTRACT Streptococcus agalactiae, a leading cause of sepsis and meningitis in ne-
onates, utilizes multiple virulence factors to survive and thrive within the human
host during an infection. Unique among the pathogenic streptococci, S. agalactiae
uses a bifunctional enzyme encoded by a single gene (gshAB) to synthesize glutathi-
one (GSH), a major antioxidant in most aerobic organisms. Since S. agalactiae can
also import GSH, similar to all other pathogenic streptococcal species, the contribu-
tion of GSH synthesis to the pathogenesis of S. agalactiae disease is not known. In
the present study, gshAB deletion mutants were generated in strains representing
three of the most prevalent clinical serotypes of S. agalactiae and were compared
against isogenic wild-type and gshAB knock-in strains. When cultured in vitro in a
chemically defined medium under nonstress conditions, each mutant and its corre-
sponding wild type had comparable growth rates, generation times, and growth
yields. However, gshAB deletion mutants were found to be more sensitive than wild-
type or gshAB knock-in strains to killing and growth inhibition by several different
reactive oxygen species. Furthermore, deletion of gshAB in S. agalactiae strain COH1
significantly attenuated virulence compared to the wild-type or gshAB knock-in strains
in a mouse model of sepsis. Taken together, these data establish that GSH is a viru-
lence factor important for resistance to oxidative stress and that de novo GSH syn-
thesis plays a crucial role in S. agalactiae pathogenesis and further suggest that the
inhibition of GSH synthesis may provide an opportunity for the development of
novel therapies targeting S. agalactiae disease.
IMPORTANCE Approximately 10 to 30% of women are naturally and asymptomati-
cally colonized by Streptococcus agalactiae. However, transmission of S. agalactiae
from mother to newborn during vaginal birth is a leading cause of neonatal menin-
gitis. Although colonized mothers who are at risk for transmission to the newborn
are treated with antibiotics prior to delivery, S. agalactiae is becoming increasingly
resistant to current antibiotic therapies, and new treatments are needed. This re-
search reveals a critical stress resistance pathway, glutathione synthesis, that is uti-
lized by S. agalactiae and contributes to its pathogenesis. Understanding the role of
this unique bifunctional glutathione synthesis enzyme in S. agalactiae during sepsis
may help elucidate why S. agalactiae produces such an abundance of glutathione
compared to other bacteria.
KEYWORDS Streptococcus agalactiae, glutathione, hydrogen peroxide, hypochlorous
acid, oxidative stress, virulence
Glutathione (GSH) is an antioxidant that is ubiquitous across all kingdoms of life andis used to protect organisms against reactive oxygen species (ROS) (1). In Strep-
tococcus agalactiae (commonly known as group B streptococcus and one of the key
causative agents for neonatal meningitis), GSH is maintained in concentrations nearly
ten times higher than in other organisms (2), suggesting that S. agalactiae relies heavily
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on GSH. While other Gram-positive streptococci, such as Streptococcus mutans and
Streptococcus pneumoniae, import GSH from their environment (3, 4), S. agalactiae
appears to rely primarily on de novo synthesis over import (5) and has been demon-
strated to produce more GSH on a per-cell basis than any organism tested (2, 3). In
addition, under oxidative growth conditions, GSH levels are approximately three times
higher than when S. agalactiae is grown under reducing conditions (2, 5). Two out-
standing questions remain: (i) why does S. agalactiae synthesize so much glutathione,
and (ii) is glutathione synthesis required for production of a robust infection?
Previously, we demonstrated that S. agalactiae synthesizes GSH using a bifunctional
enzyme, -glutamylcysteine synthetase-GSH synthetase, encoded by a single gene, the
glutathione synthesis gene gshAB (2). In contrast, humans produce two enzymes,
encoded by three genes, to facilitate GSH synthesis (6). In addition to the structural
differences of the GSH biosynthetic enzymes, the enzyme’s properties and kinetics are
significantly different between the S. agalactiae and human GSH biosynthesis enzymes
(2), giving credence to the possibility that S. agalactiae GSH synthesis could be a viable
drug target against S. agalactiae if it is found that GSH synthesis contributes signifi-
cantly to virulence.
We hypothesize that S. agalactiae synthesizes and maintains large pools of GSH in
order to survive and thrive under stressful conditions. Other antioxidant systems in S.
agalactiae have been shown to be virulence factors. For example, both superoxide
dismutase (7) and the polyene pigment -hemolysin/cytolysin (8) have been shown to
contribute to the survival of S. agalactiae inside immune cells, as well as toward the
production of a robust infection in mice. Simultaneously, GSH synthesis has been
shown to be a virulence factor in other bacteria, such as Escherichia coli (9) and Listeria
monocytogenes (10). The presence of GSH, whether synthesized or imported, has been
shown to be necessary for protecting most organisms, including other streptococci
such as S. pneumoniae (4).
To determine whether GSH synthesis could also be a virulence factor in S. agalactiae,
we set out to characterize the contribution of GSH synthesis to the viability of S.
agalactiae in a mouse model of sepsis. This study is the first step to address our central
hypothesis that S. agalactiae synthesizes GSH in response to cellular stresses in order to
use GSH to survive and thrive during an infection.
RESULTS
Generation of gshAB in-frame deletions in three serotypes of S. agalactiae. To
begin to determine the role of GSH synthesis in S. agalactiae, strains from three of the
most prevalent clinical serotypes of S. agalactiae in the United States (Ia, III, and V) were
used as the parent strains to generate two mutants each, a mutant lacking gshAB
(ΔgshAB) and a knock-in mutant (gshAB) whereby a copy of the gshAB gene derived
from 2603V/R was restored to the native location in all three deletion strains (Table 1).
Strain A909 (serotype Ia, which accounts for 23% of all U.S. S. agalactiae infections)
was isolated in the clinic from a septic neonate (11). Strain COH1 (serotype III, which
accounts for almost half of all S. agalactiae infections) was isolated from human blood
in the clinic (12). Strain 2603V/R (serotype V, which causes 9% of S. agalactiae
infections) was also isolated from a patient in the clinic (13). Together, these three
serotypes account for 80% of all S. agalactiae infections.
To determine whether the deletion of gshAB resulted in a polar mutation affecting
expression of downstream genes, quantitative PCR (qPCR) was performed for gshAB
and the first downstream gene, hyp (SAG_1821 in strain 2603V/R) on all strains
generated (wild type [WT], ΔgshAB, and gshAB) for all serotypes (Fig. 1A). As predicted,
expression of gshAB was undetectable in all of the ΔgshAB mutants, while the gshAB
knock-in (gshAB) showed comparable levels of gshAB expression to the WT for each
serotype (Fig. 1B to D). It is noteworthy that all of the gshAB knock-in strains utilized
the same gshAB gene and the upstream putative promoter region from 2603V/R, which
contains 3-bp substitutions in the 169 intergenic region and 7 amino acid substitutions
in the coding region between the various coding sequences (see Fig. S1 in the
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supplemental material). Both ΔgshAB and gshAB mutants showed comparable expres-
sion levels of hyp (SAG_1822) to the WT, for all strains, demonstrating that the gshAB
deletion and reinsertion mutations have no polar effect on the expression of down-
stream genes (Fig. 1B to D). Lastly, when the expression levels of gshAB relative to recA
were compared between WT strains, there was no significant difference between
transcript levels (data not shown).






COH1 (GCP1418) Serotype 3, hyperpigmented 29
COH1 ΔgshAB (GCP1432) COH1 with gshAB (SAN_1965*) in-frame deletion produced by allelic exchange with pGCP1422 This study
COH1 gshAB (GCP1437) GCP1432 with full-length gshAB produced using plasmid pGCP1417, WT revertant This study
2603V/R (GCP1419) Serotype 5, nonpigmented 29
2603V/R ΔgshAB (GCP1429) 2603V/R with gshAB (SAG1821*) in-frame deletion produced by allelic exchange with pGCP1422 This study
2603V/R gshAB (GCP1436) GCP1429 with full-length gshAB produced using plasmid pGCP1417, WT revertant This study
A909 (GCP1427) Serotype 1a, nonpigmented 29
A909 ΔgshAB (GCP1439) A909 with gshAB (SAK_1841*) in-frame deletion produced by allelic exchange with pGCP1422 This study
A909 gshAB (GCP1442) GCP1439 with full-length gshAB produced using plasmid pGCP1417, WT revertant This study
Plasmidsb
pGCP213 4.3-kb E. coli-streptococcal temperature-sensitive shuttle vector for allelic exchange 31
pGCP1417 pGCP213 with a gshAB (SAG1821†) full-length open reading frame for complementation This study
pGCP1422 pGCP213 with a gshAB (SAG1821†) in-frame deletion allele This study
a*, loci are based on the COH1, 2603V/R, or A909 S. agalactiae genomes, respectively; †, allelic-exchange constructs for gshAB utilized 2603V/R genomic DNA. See
Materials and Methods for details.
bAll plasmids encode an erythromycin-resistant marker.
FIG 1 Deletion and reinsertion of gshAB only affects gshAB and not downstream genes. (A) Position of SAG_1821 gshAB in reference to its first
downstream gene, SAG_1822 hyp, in strain 2603V/R as indicated. An identical genomic arrangement is present in A909 and COH1; therefore, only
2603V/R is shown as a reference. Filled block arrows represent individual open reading frames, dashed arrows indicate forward and reverse qPCR
primers, and solid line arrows represent putative operons. gshAB and hyp are predicted to be encoded in independent operons (thin arrows above
the block arrows) separated by 123 bp. Real-time qPCR was used to determine the relative transcript levels of gshAB and hyp in the ΔgshAB and
gshAB mutants compared to their respective WT strain. (B to D) Results for A909 (B), COH1 (C), and 2603V/R (D) show that the hyp levels are
approximately equivalent to that of the WT (1-fold change) for both ΔgshAB and gshAB mutants, whereas the gshAB levels are approximately
equivalent for the gshAB mutant but were undetectable for the ΔgshAB mutant (indicated by an asterisk).
Glutathione as a Virulence Factor in S. agalactiae Journal of Bacteriology
October 2019 Volume 201 Issue 20 e00367-19 jb.asm.org 3
 on O










S. agalactiae mutants lacking gshAB have growth rates, generation times, and
growth yields comparable to those of WT and gshAB S. agalactiae. To determine
the impact of GSH synthesis on bacterial growth, the growth curves, generation times,
and growth yields of the ΔgshAB and gshAB knock-in strains were measured and
compared to their WT counterparts. Thus, all of the strains and mutants were grown in
GSH-free chemically defined (CD), and optical density at 600 nm (OD600) was measured
every 15 min. Representative growth curves were produced for each strain, for which
the generation time was considered the time, during exponential growth, when the
OD600 doubled. Lastly, at 24 h postinoculation, each sample was serial diluted and
plated to quantify CFU per milliliter for the final growth yield. Representative growth
curves showed similar sizes and shapes for each strain of each serotype (Fig. 2A to C).
For all three strains (A909, COH1, and 2603V/R) of S. agalactiae tested, the generation
times of the ΔgshAB and gshAB mutants differed by 12.5% compared to the
generation time of their WT counterparts in CD medium under nonstress conditions
(Fig. 2D). These changes within strains were not significant based on the Mann-Whitney
rank sum test (n  10). However, COH1 showed significantly decreased generation
times compared to A909 and 2603V/R. Final CFU per milliliter growth yields for each
serotype showed no significant difference between the ΔgshAB and gshAB mutants
and their WT counterparts (Table 2). These data demonstrate that the absence of GSH
synthesis does not affect the growth of any of the three strains when GBS is grown
under standard, static growth conditions, suggesting that glutathione synthesis is not
required for growth under these conditions.
Both WT and gshAB S. agalactiae strains produce high levels of GSH, whereas
the gshAB strains are unable to produce GSH. To begin to evaluate the importance
of GSH to S. agalactiae when grown under static growth conditions, total GSH levels
were determined for WT, ΔgshAB, and gshAB S. agalactiae strains after growth to
FIG 2 Growth curves and generation times of WT, ΔgshAB, and gshAB S. agalactiae for strains A909, COH1, and 2603V/R were assayed by using
a standard 96-well plate assay. (A to C) A 200-l portion of GSH-free CD medium was inoculated with one bacterial colony (n  8), and the OD600
was measured every 15 min for 24 h to produce growth curves. (D) The generation time was determined using the formula for the indirect method
of determining generation time [G  t(A 0.4) – t(A 0.2)]. Error bars represent the SEM, and no significant differences were observed between WT,
ΔgshAB, and gshAB strains of any of the three serotypes, as determined by a Mann-Whitney rank sum test.
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stationary phase in GSH-free CD medium using a standard GSH recycling assay. As
expected, mutants lacking gshAB were unable to synthesize detectable levels of GSH,
whereas all of the gshAB and WT S. agalactiae strains exhibited measurable levels of
GSH (Fig. 3). Notably, S. agalactiae 2603V/R was observed to produce 10 to 13 times
more GSH compared to A909 and COH1 (ca. 350 to 400 nM/mg protein versus ca. 25
to 50 nM/mg protein, respectively) (Fig. 3). Because all of the gshAB knock-in strains
utilized the same gshAB gene from 2603V/R and yet only 2603V/R displayed high GSH
concentrations, sequence differences in the promoter region and/or coding sequence
of gshAB do not account for differences in GSH production between strains (Fig. S1).
Together, these data not only demonstrate that gshAB is required for de novo GSH
synthesis in S. agalactiae but also highlight that an at least 2-fold greater amount of
GSH than other bacteria such as E. coli (14) is synthesized, de novo, by representative
strains from the three of the most clinically prevalent serotypes of S. agalactiae in the
United States.
GSH synthesis in S. agalactiae protects against ROS stress under atmospheric
conditions. To address the impact of glutathione synthesis on the sensitivity to ROS, S.
agalactiae was tested for ROS susceptibility on solid media by measuring the zone of
growth inhibition surrounding ROS infused discs. Prior to experimentation, the assay
was calibrated to use concentrations of hypochlorous acid (HOCl) and hydrogen
peroxide (H2O2) that produced a 5-mm zone of inhibition for WT 2603V/R S. agalac-
tiae (Fig. S2). Thus, WT and ΔgshAB S. agalactiae for all three strains was tested for
growth inhibition utilizing two model ROS (HOCl and H2O2) and compared to
phosphate-buffered saline (PBS) as a nonstressed control (which showed no zone of
inhibition [data not shown]) or erythromycin as a non-ROS control for stress (Fig. 4). As
shown, all three strains had the same pattern of exhibiting an increase in zones of
inhibition for the ΔgshAB mutants relative to WT and gshAB strains for both H2O2 and
HOCl but no differences in the presence of erythromycin (Fig. 4). However, the increase
in the zones of inhibition was not uniform across strains (Fig. 4). In addition, in COH1,
TABLE 2 Growth yields of S. agalactiae wild-type and mutant strains after growth for 24 h
in CD medium
Strain
Avg CFU/ml  SEMa
A909 COH1 2603V/R
Wild type 1.00E8  4.62E7 3.71E7  1.47E7 5.83E7  4.71E6
ΔgshAB mutant 7.40E7  1.33E7 2.71E8  9.80E7 6.20E7  5.48E6
gshAB mutant 6.01E8  1.83E8 1.12E8  5.97E7 7.75E7  1.76E7
an  4. Results were not statistically significant between any of the strains for any of the serotypes.
FIG 3 Glutathione production of WT, gshAB, and gshAB S. agalactiae. WT, ΔgshAB, and gshAB S.
agalactiae strains were grown overnight at 37°C in GSH-free CD medium prior to GSH analysis. Three
serotypes were assayed: A909, COH1, and 2603V/R. A “#” symbol indicates that the ΔgshAB mutant was
below limit of detection (1 nmol/mg), error bars represent the SEM, and an asterisk indicates a significant
difference (P  0.05). To determine the significance between ΔgshAB and WT strains and between
ΔgshAB and gshAB strains, the limit of detection (1 nmol/mg) was assumed for all ΔgshAB values. There
was no significant difference determined by the Mann-Whitney rank sum test between WT and gshAB
strains for any of the three serotypes.
Glutathione as a Virulence Factor in S. agalactiae Journal of Bacteriology
October 2019 Volume 201 Issue 20 e00367-19 jb.asm.org 5
 on O










the gshAB mutant subjected to H2O2 stress was more similar to the ΔgshAB mutant
than to the WT. These results suggest that while in some strains GSH exhibits a modest
protective role, in other strains the protection is minimal and not significant.
To further quantify whether and how GSH synthesis protects S. agalactiae against
ROS, the MICs, as well as minimal bactericidal concentrations (MBCs), for H2O2 and HOCl
in GSH-free (CD) medium (Fig. 5) were determined for the three strains. Differential
bacterial inhibition and killing were observed among the strains for both stress con-
ditions. For H2O2, only 2603V/R (Fig. 5E) showed a decrease in MIC when GSH synthesis
was not present in comparison to both WT and gshAB strains. However, for HOCl,
strains A909 (Fig. 5A) and COH1 (Fig. 5C) showed a decreased MIC when GSH synthesis
was removed. For bacterial killing, both A909 (Fig. 5B) and 2603V/R (Fig. 5F) ΔgshAB
mutants showed increased MBC to H2O2, with only 2603V/R (Fig. 5F) showing an
increased MBC against the ΔgshAB mutant when exposed to HOCl. Together, the MIC
and MBC data suggest that different levels of GSH synthesis may provide S. agalactiae
with different levels of protection against ROS, since the strain that produced the most
GSH (2603V/R) was protected under a majority of the stress conditions (Fig. 5E and F).
S. agalactiae deficient in GSH synthesis exhibit decreased virulence and bac-
terial burden in a mouse sepsis model of infection. To determine whether GSH is a
virulence factor for S. agalactiae, 8- to 10-week-old C57BL/6 mice (n  10) were
challenged with 108 CFU of WT, gshAB, or gshAB S. agalactiae COH1 by intravenous
injection. Strain COHI was chosen for in vivo challenge because (i) it is a representative
of the most common serotype (III) causing S. agalactiae neonatal meningitis (15) and (ii)
it produced the least amount of GSH in comparison to A909 and 2603V/R (Fig. 3).
Therefore, if GSH synthesis was deemed to be a virulence factor in the COH1 serotype,
then the results would likely apply to other serotypes that produce more GSH. Mice
were monitored twice daily after infection, and a Kaplan-Meier analysis revealed that
GSH-producing S. agalactiae COH1 was significantly (P  0.0001) more virulent than
GSH-deficient S. agalactiae COH1, as determined by the percent survival over the
course of 6 days (Fig. 6A). Quantification of the bacterial burden revealed a significantly
higher bacterial load in the blood for GSH-producing bacteria at both 4 h postinfection
FIG 4 Bacterial growth restriction on solid media in response to H2O2, HOCl, and erythromycin. Bacterial
growth restriction was assessed between WT, ΔgshAB, and gshAB strains grown in the presence of
750 mM H2O2 (A), 589 mM HOCl (B), or 15 g of erythromycin (C). Error bars represent the SEM with n 
3, and asterisks indicate a significant difference (*, P  0.05; **, P  0.01; ***, P  0.001) between WT and
ΔgshAB strains, as determined by a Mann-Whitney rank sum test.
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(P  0.001) and at the time of death or the end of the experiment (day 6) (Fig. 6B).
These results suggest that GSH synthesis is indeed a virulence factor for S. agalactiae,
since mutants deficient for GSH synthesis were unable to produce a robust septic
infection despite the presence of the equivalent starting inoculum.
FIG 5 MICs (A, C, and E) and MBCs (B, D, and F) of H2O2 and HOCl on S. agalactiae serotypes A909 (A and B), COH1
(C and D), and 2603V/R (E and F). Asterisks indicate a significant difference (*, P  0.05; **, P  0.01). WT and gshAB
strains were not significantly different for any condition, except the H2O2 MIC for A909. Error bars represent the
SEM, and significance was determined by a Mann-Whitney rank sum test (n  4).
FIG 6 GSH is essential for full virulence of S. agalactiae in mice. (A) WT, gshAB, and gshAB S. agalactiae strains
produce significantly different survival profiles depending on the GSH synthesis ability following intravenous
challenge of C57BL/6 mice. Murine survival is significantly different (P  0.0001) between WT/gshAB and ΔgshAB
strains. (B) Bacterial loads (as measured in blood) are significantly higher at 4 h postinfection and at the time of
death (TOD) for bacteria able to synthesize GSH. Significance for survival was determined by using Kaplan-Meier
analysis, whereas the significance for the bacterial load was determined by using a Mann-Whitney rank sum test
with n  10.
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To begin to evaluate the roles of GSH synthesis in S. agalactiae, ΔgshAB and gshAB
mutants were generated in three strains of S. agalactiae (A909, COH1, and 2603V/R). We
found, using qPCR, that the creation of the mutants did not result in any polarity effects
(Fig. 1). By comparing responses to oxidative stresses, we observed that S. agalactiae
lacking gshAB was modestly more sensitive to the ROS stress conditions than were WT
and gshAB S. agalactiae strains (Fig. 4 and 5). By comparison, S. agalactiae lacking
gshAB was significantly less virulent in a mouse model of sepsis than were WT and
gshAB S. agalactiae (Fig. 6). These results strongly suggest that GSH synthesis con-
tributes minimally to ROS stress resistance and significantly toward the virulence of S.
agalactiae. Since GSH synthesis is not universal among bacterial species, and the S.
agalactiae GSH synthetic enzyme is distinct from the human biosynthetic enzymes,
these results suggest that GSH synthesis could be a viable drug target that would be
more selective and specific than the broad-spectrum antibiotics currently used to
prevent S. agalactiae infections in neonates. Although GSH synthesis has been shown
to correlate with the virulence of L. monocytogenes, this is the first study to our
knowledge to directly correlate GSH synthesis to virulence in S. agalactiae.
To determine whether GSH synthesis impacted bacterial growth of S. agalactiae, the
growth curves, generation times, and growth yields of the ΔgshAB and gshAB mutants
were measured and compared to their WT counterparts. Our results suggest that GSH
synthesis in S. agalactiae is not required for aerobic, nonstressed growth of S. agalac-
tiae, since deletion of the gshAB gene did not cause a growth defect under nonstress
conditions (Fig. 2). However, deletion of the gshAB gene did result in more sensitivity
to ROS stress in about half of the cases considered (Fig. 4 and 5), suggesting that GSH,
at least in part, assists S. agalactiae in neutralizing ROS stress. The ability to maintain WT
growth rates under nonstress conditions demonstrates that the increased ROS sensi-
tivity seen in the ΔgshAB mutants is due to the lack of GSH synthesis and not an
off-target, general growth defect. These results are consistent with previous reports
from other bacteria, since ROS sensitivity has been observed when GSH synthesis was
removed from E. coli (9) and L. monocytogenes (10), as well as when GSH import was
removed from S. pneumoniae (4).
We have previously shown that S. agalactiae produces robust quantities of GSH
compared to other bacteria, including common pathogens (2). Results from the present
study suggest that even within S. agalactiae strains, there is a large variation in GSH
production. Specifically, 2603V/R produces approximately 10 to 13 times greater levels
of GSH compared to COH1 (Fig. 3). There are very few, mostly conservative differences
in the protein sequence and upstream intergenic sequence between the different
strains (Fig. S1), and the same gene sequence from 2603V/R (SAG1821) was utilized to
generate the GSH-deficient mutants and the GSH knock-in strains in all three strains.
The fact that all three gshAB mutants restored gshAB expression (Fig. 1) and the GSH
concentration to levels similar to their WT counterparts (Fig. 3) suggests that differ-
ences in promoter regions and/or amino acid substitutions are not responsible for the
differences in GSH levels between the strains and that perhaps other undefined
regulatory elements are involved. Alternatively, it is possible that this increase in GSH
production in 2603V/R could be associated with the lower levels of granadaene, a
carotenoid pigment which also has antioxidant capabilities, produced by 2603V/R in
comparison to COH1 (16). Because COH1 produces large quantities of granadaene (16),
it presumably does not require high quantities of other antioxidants, such as GSH, to
combat ROS. This hypothesis has yet to be tested, but it will be a focus for a future
study involving mutants lacking the ability to synthesize granadaene.
Although there is a large difference between the amount of GSH produced among
S. agalactiae strains, even the least-productive strain, COH1, still produces more GSH
per cell than any other prokaryotic organism previously reported. For example, Esche-
richia coli, a Gram-negative bacterium, is the model organism for GSH synthesis in
bacteria (14), and yet it synthesizes 2-fold less GSH than S. agalactiae COH1 (17). It is
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important to note that E. coli uses the more common pathway of two enzymes for GSH
synthesis, whereas S. agalactiae uses the less common mechanism of a single bifunc-
tional enzyme (gshAB) (2). However, other Gram-negative bacteria, such as Pasteurella
multocida, synthesize GSH using a bifunctional enzyme, similar to S. agalactiae, and yet
still produces much smaller quantities (18). Even when S. agalactiae is compared to L.
monocytogenes, another Gram-positive organism with a bifunctional GSH synthesis
enzyme, the GSH levels of S. agalactiae are much higher (17). These observations
indicate that the Gram status and mechanism of synthesis are not predictive of GSH
production levels.
When S. agalactiae is compared to its human host, whose cells typically produce
millimolar levels of GSH, S. agalactiae still synthesizes 2- to 10-fold-higher quantities of
GSH, depending on the strain of S. agalactiae (19). The unique abundance of GSH
suggests that GSH synthesis is important for S. agalactiae biology and that there may
be additional roles for GSH beyond its antioxidant properties in S. agalactiae. For
example, GSH has been shown to help in the detoxification of metal stresses (4, 20) and
chlorine compounds (21), which can be regulated by oxygenation or starvation path-
ways (21). S. agalactiae, along with other streptococci species, is also able to import
differing levels of GSH (3). Future studies will further characterize the ability of S.
agalactiae to import GSH, in conjunction with its ability to synthesize such large
quantities of GSH. It is likely that different environmental stimuli promote import versus
synthesis and that GSH has more than one role in S. agalactiae.
To begin to understand why S. agalactiae produces and maintains such elevated
levels of GSH, the role of glutathione synthesis was quantified in S. agalactiae in
response to H2O2 and HOCl, two ROS that GSH has been shown to provide cellular
protection against in other bacteria (4, 18, 20). As expected, some of the ΔgshAB
mutants showed growth inhibition using a disk assay in response to H2O2 and HOCl but
not to a non-ROS control, erythromycin (Fig. 4). Although none of the ΔgshAB mutants
showed growth inhibition to erythromycin, surprisingly, only the ΔgshAB mutants for
A909 and 2603V/R showed significant growth inhibition in response to ROS stress
between their WT and gshAB strains, whereas COH1 showed no inhibition for either
stress (Fig. 4A and B). Again, this result could be due to the redundant antioxidant
systems seen in S. agalactiae, particularly the antioxidant granadaene pigment seen in
COH1 (22). However, another explanation for the lack of sensitivity of COH1 may be
related to the method employed to investigate ROS sensitivity, namely, growth on a
brain heart infusion (BHI) agar plate, which may allow for some limited amount of GSH
import.
To further quantify the protection against H2O2 and HOCl, MIC and MBC values for
each ROS were determined for the three strains. For a majority of the cases tested, there
was a significant or trending difference between WT/gshAB and ΔgshAB strains, with
COH1 being the least susceptible to ROS stresses and 2603V/R being the most suscep-
tible. Therefore, it appears that GSH synthesis levels (Fig. 3) largely correlate with ROS
susceptibility, as seen in the disk assay.
It is important to note that the ROS susceptibility assay and the MBC assay utilized
bacterial plating on BHI agar plates, whereas the MIC assay did not require plating, and
therefore the bacteria were only in contact with CD medium lacking glutathione.
Because it is hypothesized that S. agalactiae is able to import GSH (3), this import of
GSH could have an impact on these results. However, the murine model of sepsis
utilized only BHI medium for growth, and a significant difference was seen in murine
disease and bacterial infection loads, suggesting that GSH import is not sufficient to
rescue S. agalactiae lacking GSH synthesis during infection (Fig. 6).
There are multiple factors that may explain the differential effects of HOCl and H2O2
in the assays used. First, HOCl is one of the most potent bactericidal substances because
it is a strong electrophile capable of oxidizing many important biological molecules
(23). Interestingly, HOCl is especially toxic to molecules containing thiols, like GSH (24),
thus making GSH an ideal antioxidant for S. agalactiae to defend against HOCl. Bacteria
possess very few mechanisms capable of defending against chlorine stresses, which
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likely explains why neutrophils utilize HOCl as a main source for bacterial killing (25).
However, the same features that make HOCl bactericidal also make it harmful to
immune cells. During the oxidative burst, immune cells utilize GSH to react with and
protect against HOCl, thereby protecting against self-inflicting damage (26). Therefore,
it is likely that S. agalactiae utilizes GSH in a similar manner to protect against cellular
damage caused by the oxidative burst of the immune cells. Our data suggest that GSH
synthesis is an important mechanism by which S. agalactiae protects itself against HOCl.
Second, the greater effectiveness of HOCl (micromolar) versus H2O2 (millimolar) in
the MBC assay may be due to the fact that the MIC assay measures the resistance of
cells growing in the exponential phase, whereas the MBC assay examines bacteria in
the stationary phase. In the presence of HOCl, GSH becomes sacrificial (9), detoxifying
the HOCl, but then is nonrecyclable. In other words, in contrast to H2O2, HOCl-oxidized
GSH cannot effectively be reduced by GSH reductase to reduced GSH, and thus the
restoration of GSH levels after HOCl detoxification is dependent on de novo synthesis.
A third explanation for the extreme decrease in HOCl required to kill S. agalactiae
observed in the MBC assay compared to H2O2 (Fig. 5) could be due to hydrogen
peroxidases. Unlike other streptococcal species which produce GSH peroxidase (27), S.
agalactiae does not appear to encode such an enzyme and instead likely uses GSH
directly to detoxify H2O2 and also uses a GSH-independent peroxidase, alkyl hydrogen
peroxidase C (28), which can detoxify H2O2 but not HOCl. The presence of a GSH-
independent peroxidase may allow the GSH-deficient bacteria to survive more effi-
ciently against H2O2 than HOCl, which would explain why much lower concentrations
of HOCl cause bacterial killing compared to H2O2 concentrations.
Our results show that without the gshAB gene, S. agalactiae COH1 is less virulent
than it is with the gshAB gene. We hypothesize that the attenuated virulence is due to
the lack of synthesis of GSH. However, an alternative hypothesis regarding the enzyme
expressed by gshAB, -glutamylcysteine synthetase-glutathione synthetase, is that the
enzyme itself may be required for virulence by interacting with other proteins and/or
molecules and not just by synthesizing the end product, GSH. While we have not ruled
out the alternative hypothesis, we plan to test that hypothesis in a future study. In the
meantime, our results are consistent with what is observed for another Gram-positive
pathogen, Listeria monocytogenes (10), which has been shown to utilize GSH itself as a
virulence factor. It is reasonable to conclude that S. agalactiae is also using GSH itself
as a virulence factor. In addition, based on other bacteria, it is very likely that GSH may
have other roles other than GSH detoxification, such as protection against heavy metals
or regulation of virulence factors. Our present study begins to analyze potential
mechanisms, and further studies are under way in our lab to evaluate other mecha-
nisms and roles for GSH.
In summary, this study demonstrates that the presence of the GSH synthesis
gene contributes to S. agalactiae virulence and plays a small role in ROS resistance.
Because having the gshAB gene allows for virulence in COH1, and COH1 synthesizes
the smallest amount of GSH compared to the other strains of S. agalactiae tested,
GSH synthesis could be a mechanistic target for future treatments of S. agalactiae.
Thus, future studies will focus on elucidating the cellular regulation of GSH syn-
thesis, as well as the other roles GSH may play in S. agalactiae, including immune
cell evasion, cell signaling, virulence gene expression, colonization, and GSH trans-
port (import and export).
MATERIALS AND METHODS
Bacterial strains. S. agalactiae 2603 V/R (ATCC BAA-611 [29]), A909 (ATCC BAA-1138 [29]), and COH1
(ATCC BAA-1176 [29]) were used as parental strains to generate the ΔgshAB and gshAB strains of S.
agalactiae used in this study. Construction of the ΔgshAB and gshAB strains of S. agalactiae are
described below, and the mutant derivatives generated are listed in Table S1 in the supplemental
material.
Bacterial growth. To construct the S. agalactiae mutants, bacteria were grown in Todd-Hewitt
medium (Difco) supplemented with 0.2% yeast extract (Difco) (THY medium) in sealed culture tubes at
37°C under static conditions. Solid medium for construction of the S. agalactiae mutants was prepared
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by the addition of 1.4% Bacto agar (Difco) (THY agar). When appropriate, erythromycin at 1 g ml	1 was
added to the medium during generation of S. agalactiae mutant derivatives.
Routine culture of the S. agalactiae parent and mutant strains, once constructed, involved creating
fresh streak plates for isolation of the bacteria on agar plates composed of BHI broth and 1.5% Bacto agar
(Difco), followed by incubation at 37°C under atmospheric conditions. For each experiment, colonies
were inoculated from solid medium and grown in CD liquid medium, which is naturally free of GSH (30).
Prior to experiments, all cultures were grown in CD medium with loosely capped lids. Cultures were
grown overnight (18 h) at 37°C in a shaking incubator with 200 rpm to ensure cultures received
sufficient and constant aeration.
Construction of GSH-deficient S. agalactiae and knock-in strains. Routine molecular cloning and
plasmid propagation utilized E. coli DH5 that was cultured in Luria-Bertani medium at 37°C. When
appropriate, erythromycin at 500 g ml	1 was added to the medium, and X-Gal (5-bromo-4-chloro-3-
indolyl--D-galactopyranoside) at 40 g ml	1 was added to solid medium.
Plasmid DNA was isolated via standard techniques and used to transform E. coli using standard
methods. In-frame deletion and complementation mutants of gshAB (NCBI reference sequence
NC_004116.1) were generated using the temperature-sensitive shuttle vector pGCP213 (31) to construct
the mutagenic plasmids listed in Table S2 in the supplemental material. The gshAB deletion allele (lacking
amino acids 17 to 733) and complementation allele (restoring complete open reading frame encoding
750 amino acids) were generated by PCR using the oligonucleotide primers (IDT) listed in Table S1
through a process of overlap extension PCR (32) and utilizing genomic DNA isolated from strain 2603V/R
by a commercially available kit (Wizard Genomic DNA; Promega) as the template. Modified alleles were
inserted directly into pGCP213 at the M13F and M13R universal primer binding sites utilizing the overlap
extension PCR cloning method described in detail elsewhere (33). The fidelity of all molecular constructs
and mutated chromosomal loci were confirmed by PCR and determination of the DNA sequences
(Genewiz) using primers of the appropriate sequences. Plasmid DNA was isolated by standard methods
(Hurricane Maxi-Prep [Gerard Biotech], followed by ethanol precipitation) and used to transform S.
agalactiae, as previously described with minor modifications (34). Transformants appeared after 2 to
4 days at 30°C on THY agar containing erythromycin. Passaging of temperature-sensitive mutagenic
plasmids and screening for S. agalactiae mutants was performed as previously described with minor
modifications (35). After two consecutive days of passaging at 37°C, overnight cultures were diluted at
1:10,000 into fresh THY medium in the absence of erythromycin at 30°C and then passaged daily until
the desired mutants were isolated. To isolate mutants, overnight cultures were spread onto THY agar and
incubated overnight at 30°C. Colonies were then screened for erythromycin sensitivity by replica plating,
and sensitive colonies were screened by colony PCR for the presence of a mutated allele. Of note, all
gshAB knock-in strains were generated with the 2603V/R allele.
RNA transcript levels of GSH-deficient and GSH knock-in S. agalactiae verified by qPCR.
Transcript abundances of select genes were analyzed by real-time reverse transcription-PCR, referred to
here as qPCR. For gshAB gene expression analysis, overnight cultured cells were diluted 1:25 or 1:10 into
fresh CD medium and harvested at logarithmic phase for mRNA extraction. Select genes, gshAB and hyp
(SAK_1842), were analyzed by qPCR and normalized to recA using the primers listed in Table S2. gshAB
and hyp (SAK_1842) transcript is displayed as threshold cycle (ΔCT), normalized to recA for each strain,
normalized to the wild type (36). RNA data shown are means and standard errors of the means (SEM)
derived from four biological replicates run in duplicate.
Bacterial growth analysis. To determine whether GSH synthesis, or the lack thereof, affects the
growth of S. agalactiae strains under nonstressed conditions, a growth analysis in CD (GSH-free) medium
was performed. Briefly, 200 l of CD medium was placed into each well of a 96-well microtiter plate.
Individual wells were inoculated with a single colony from a BHI plate from each of the bacterial strains
(n  12). Growth at 37°C was monitored in a PowerWaveX plate reader (Bio-Tek Instrument, Inc.). During
growth, the plate was shaken for 5 s every 15 min for the duration of 24 h, and the OD600 was measured
every 15 min. Each data point was then plotted, creating a standard bacterial growth curve. The
generation time, or doubling time, was determined using the formula for the indirect method of
determining generation time [G  t(A 0.4) – t(A 0.2)]; the lag phase and stationary phase were both excluded
from analysis. The average generation time for each mutant was then compared to its respective wild
type. Growth yields were determined by performing 10-fold serial dilutions from cultures grown for 24 h
in CD medium under static conditions and plating onto BHI agar to calculate the CFU per milliliter.
Growth curves were produced using a representative biological replicate for each stain, and generation
times were produced using a minimum of six biological replicates.
Determination of GSH levels. To compare GSH levels between the three serotypes, as well as to
determine whether GSH synthesis was indeed eliminated by removing the gshAB gene, the total
intracellular GSH levels were measured in WT, ΔgshAB, and gshAB S. agalactiae A909, COH1, and
2603V/R strains after overnight growth in CD (GSH-free) medium using a routine GSH reductase enzyme
recycling assay (37). Quantitation was performed using a standard curve constructed with 0 to 5 nmol of
GSH. To normalize the samples per mg of total protein, the protein concentration was analyzed in the
unprecipitated sample using a bicinchoninic acid protein concentration kit (Pierce). The GSH levels
shown are the means and SEM of n  3 biological replicates.
S. agalactiae susceptibility to oxidative stresses and erythromycin. To determine how GSH
synthesis, or the lack thereof, protects S. agalactiae from either ROS or general susceptibility to
antibiotics, a standard antibiotic disk assay (38) using H2O2, HOCl, or erythromycin (a common antibiotic
used to treat S. agalactiae in patients) was performed. First, to determine the dose of ROS to use in the
disk assay, a dose-response curve for HOCl and H2O2 inhibition of growth on solid medium was
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performed using WT 2603V/R S. agalactiae spread onto quadrants of a BHI agar plate. One sterile disk
(Becton Dickinson) was placed within each quadrant, and 10-l portions of 2-fold dilutions of HOCl, H2O2,
or PBS were placed on the disk. The plates were incubated at 37°C under aerobic conditions for 24 h, and
the zones of inhibition were recorded. After determining the growth-inhibitory concentrations for
2603V/R, the assay was then used to measure the zones of inhibition for all WT, ΔgshAB, and gshAB S.
agalactiae strains using 589 mM HOCl, 750 mM H2O2, 15 g of erythromycin (Hardy Diagnostics), and PBS
(nonstressed control) under aerobic growth conditions. Briefly, overnight cultures grown in CD medium
were normalized to an OD600 of 0.1 in PBS, and 100 l of normalized bacteria was spread onto separate
quadrants of a BHI quad plate in which there are four distinct partitions made of plastic (Midwest
Scientific). The ROS stress embedded on a sterile disk, on an erythromycin antibiotic disk, or on PBS
embedded on a sterile disk was placed in the center of each quadrant, and plates were incubated
overnight at 37°C under standard atmospheric conditions. The zones of inhibition, in millimeters, were
then measured to determine the susceptibility to the ROS, the erythromycin, or the PBS control. The
zones of inhibition shown are the mean and SEM for n  7 biological replicates.
MIC assays of oxidative stresses to S. agalactiae. To determine how GSH synthesis, or the lack
thereof, protects S. agalactiae from growth inhibition by ROS, MIC assays were performed for two model
ROS, hydrogen peroxide (H2O2; Sigma-Aldrich) and hypochlorous acid (HOCl; Sigma-Aldrich), in CD
(GSH-free) medium. The MICs for H2O2 and HOCl were determined by incubating the WT, gshAB, and
gshAB S. agalactiae COH1 strains with 0 to 68.8 mM H2O2 or with 0 to 31.5 mM HOCl. Using a 96-well
microtiter plate, each ROS was subjected to 2-fold serial dilution with CD medium for a working volume
of 100 l per well. Separate CD medium was then inoculated with the appropriate bacterial strain by
adding 100 l of a bacterial solution consisting of fresh bacterial colonies derived from a BHI agar plate
into CD medium normalized to an OD600 of 0.1 for a final volume of 200 l. Plates were incubated
overnight under static aerobic conditions for 18 h at 37°C. After incubation, OD600 measurements were
recorded on a PowerWaveX plate reader to detect bacterial growth in response to the various concen-
trations of H2O2 and HOCl. The MIC was considered the point at which growth was inhibited 99%
compared to the nonstressed control. The MICs shown are the mean and SEM for n  4 biological
replicates.
Minimum bactericidal concentration assays of oxidative stresses to S. agalactiae. To determine
how GSH synthesis, or the lack thereof, protects S. agalactiae from ROS-mediated killing, minimum
bactericidal concentration (MBC) assays were performed for the same two model ROS, H2O2 and HOCl,
in CD (GSH-free) medium. The MBCs for H2O2 and HOCl were determined by subjecting S. agalactiae that
had been previously grown to stationary phase in CD medium with 0 to 68.8 mM H2O2 and with 0 to
492.2 M HOCl in fresh CD medium. Briefly, using a 96-well microtiter plate, each ROS was subject to
2-fold serial dilution with PBS for a working volume of 100 l per well. Bacteria grown to stationary phase
in CD medium were normalized in PBS to an OD600 of 0.5. Then, 100 l of the normalized bacteria was
added to various concentrations of H2O2 and HOCl. The plate was then incubated for 1 h at 37°C under
aerobic conditions. After incubation, each condition was subjected to 10-fold serial dilution and plated
on BHI agar. CFU were calculated to determine the MBC for each bacterial strain. The MBC was
considered the point at which 1 log less viability occurred compared to the control with no stress. The
MBCs shown are the mean and SEM for n  3 biological replicates.
In vivo murine model of sepsis for S. agalactiae COH1. To determine whether GSH synthesis
mediated by gshAB is a virulence factor in S. agalactiae, a murine model of sepsis was utilized (16). The
animal protocol was approved by the Saint Louis University IACUC, protocol 2201, which ensured that
death was not used as an endpoint. Briefly, 8- to 10-week-old C57BL/6 mice (Jackson Laboratories) were
injected in the tail vein with a targeted dose of 107 CFU of logarithmic-phase WT, ΔgshAB, or gshAB
S. agalactiae COH1 strains. Bacteremia was assessed at 4 h postinfection by submandibular blood
collection; samples were serial diluted and plated on BHI plates. Mouse health and survival was
monitored twice daily for 6 days, moribund mice were immediately sacrificed, and all remaining mice
were sacrificed at day 6. Bacterial loads at the time of death were determined by serially diluting and
plating blood from cardiac punctures taken after euthanasia. The survival curves and bacterial loads
shown are the mean and SEM for n  20 biological replicates.
Statistical analysis. A Mann-Whitney rank sum test was used for all comparisons (n  3). In all cases,
WT and gshAB strains were compared to the ΔgshAB strain, with WT and gshAB strains showing no
significant differences for most experiments (unless otherwise noted).
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